Pfizer snaps up migraine drugmaker Biohaven for $11.6bn : vi

Pfizer snaps up migraine drugmaker Biohaven for $11.6bn

Acquiring Biohaven is Pfizer’s biggest deal in years and will allow the company to commercialise the Nurtec medication for migraine attacks.

Related Keywords

New Haven , Connecticut , United States , Nick Lagunowich , Pfizer , Reuters , Acquiring Biohaven , Pfizer Internal ,

© 2025 Vimarsana